Key result
A 54-year-old healthy woman developed acute pericarditis 7-10 days after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine, which resolved completely with anti-inflammatory therapy.
Why the study?
There were no reports in the literature of acute pericarditis after BNT162b2 vaccination, despite known associations with COVID-19 infection and emerging evidence of post-vaccine myocarditis.
Does the Pfizer-BioNTech COVID-19 mRNA vaccine cause acute pericarditis in a healthy middle-aged woman?
Case Report (n=1)
No
Does the Pfizer-BioNTech COVID-19 mRNA vaccine cause acute pericarditis in a healthy middle-aged woman?
This case report highlights acute pericarditis as a potential rare adverse reaction following mRNA COVID-19 vaccination that responds well to standard anti-inflammatory therapy.
Suggests possible post-vaccination pericarditis; leaves open causality and incidence in larger cohorts.
A two-dose regimen of Pfizer-BioNTech COVID-19 vaccination confers 95% protection against COronaVIrus Disease 19 (COVID-19) and the safety profile is adequate. To the submission date, there were no reports in literature of acute pericarditis after BNT162b2 vaccination. However, pericarditis has been reported as a rare event associated with COVID-19 infection, which could be due to the pro-inflammatory effects of the spike protein. Recent evidence of post-vaccine myocarditis has been published. Herein we describe the case of a middle-aged healthy women who developed symptoms and signs of acute pericarditis 7-10 days after the second dose of Pfizer-BioNTech COVID-19 vaccination. Although a direct effect cannot be stated, it is important to report a potential adverse vaccine reaction effect that could be associated with the expression of SARS-CoV-2 spike protein induced from the mRNA of the vaccine.
No takes yet. Share an insight, caveat, or question.
Sonaglioni et al. (2021) conducted a case report in Acute pericarditis (n=1). Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2 was evaluated on Development of acute pericarditis. A 54-year-old healthy woman developed acute pericarditis 7-10 days after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine, which resolved completely with anti-inflammatory therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: